Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
79.17
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5
Open
79.17
Bid (Size)
75.75 (1)
Ask (Size)
80.05 (1)
Prev. Close
79.17
Today's Range
79.17 - 79.17
52wk Range
55.02 - 98.40
Shares Outstanding
47,190,970
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Via
InvestorPlace
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Performance
YTD
+2.74%
+2.74%
1 Month
-3.80%
-3.80%
3 Month
-5.31%
-5.31%
6 Month
+9.55%
+9.55%
1 Year
+28.71%
+28.71%
More News
Read More
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
March 25, 2024
Via
Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
March 19, 2024
Via
Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
February 27, 2024
Via
Benzinga
Earnings Outlook For Axsome Therapeutics
February 19, 2024
Via
Benzinga
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
March 23, 2024
Via
The Motley Fool
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings For Axsome Therapeutics
February 06, 2024
Via
Benzinga
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
February 26, 2024
Via
InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
February 26, 2024
Via
The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
February 20, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
February 20, 2024
Via
Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
February 20, 2024
Via
Investor's Business Daily
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 20, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
2 Stocks That Could Double Your Money in 5 Years
February 08, 2024
Via
The Motley Fool
Earnings Scheduled For February 20, 2024
February 20, 2024
Via
Benzinga
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
Via
Benzinga
5 medical stocks growing earnings by triple digits
February 06, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
January 26, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.